← All trials
NCT00672191
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2008
- Primary completion
- Aug 1, 2010
- Completion date
- Nov 1, 2011
- First posted
- —
- Last posted
- —
- Enrollment
- 59
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Argos TherapeuticsLead sponsor
- Hamilton Health Sciences CorporationOverall official - principal investigator
- University of TorontoOverall official - principal investigator
- Maple Leaf ClinicOverall official - principal investigator
- Clinque Medical du Quartier LatinOverall official - principal investigator
- Clinque medicale l'ActuelOverall official - principal investigator
- McGill UniversityOverall official - principal investigator
- University of MontrealOverall official - principal investigator
- University of OttawaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.